Everything below concerns dose range. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-09. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
=== 1950s === 1954: Jack Bush purchases the rights to a new membrane-production process developed by Lovell Chemical Company. Millipore Filter Corporation is incorporated and Bush becomes president, and later chairman 1955: Millipore receives its first patent, for microporous nylon film invented by Stanley Lovell and Jack Bush
== Synthesis == Pancreatic polypeptide is synthesised and secreted by PP cells (also known as gamma cells or F cells) of the pancreatic islets of the pancreas. These are found predominantly in the head of the pancreas.
USDA RDA chart in PDF format Archived 9 November 2021 at the Wayback Machine Health Canada Dietary Reference Intakes Reference Chart for Vitamins NIH Office of Dietary Supplements: Fact Sheets Archived 16 September 2008 at the Wayback Machine "Vitamins and minerals". nhs.uk. 23 October 2017.
== Personal life == Austin played college football at the University of North Texas. Austin married his high school girlfriend Kathryn Burrhus on November 24, 1990. However, he later pursued a relationship with English wrestling manager Jeanie Clarke, with whom he was working. His marriage to Burrhus was annulled on August 7, 1992, while he was in Japan and he married Clarke on December 18, on his 28th birthday. They had two daughters before divorcing in 1999. Austin also adopted Clarke's daughter from a previous relationship with Chris Adams. Austin's adoptive daughter was married to fellow professional wrestler Adam Bryniarski until his death in 2022. In 1998, Austin was the recipient of Hamilton, Ontario's "Key to the City", he is one of two people to ever be bestowed the honor, the other being the basketball player Shai Gilgeous-Alexander. That same year on September 1, the city of Lowell, Massachusetts declared that date Stone Cold day along with naming a street after him for the day. The date March 16 is commonly associated with Austin due to the date matching up with his wrestling catchphrase "Austin 3:16". On September 13, 2000, Austin married wrestling manager Debra Marshall. On June 15, 2002, Marshall called the police to the couple's home. She told officers that Austin had hit her and then stormed out of the house before police arrived. An arrest warrant was issued by the Bexar County district attorney's office on August 12 and Austin turned himself in the following day, at which point he was charged with domestic abuse.
Sources: en.wikipedia.org
Despite guidelines recommending that intensive blood sugar control be based on balancing immediate harms with long-term benefits, many people – for example people with a life expectancy of less than nine years who will not benefit, are over-treated. It is recommended that all people with type 2 diabetes get regular eye examinations. There is moderate evidence suggesting that treating gum disease by scaling and root planing results in an improvement in blood sugar levels for people with diabetes.
Estrogens, in females, are produced primarily by the ovaries, and during pregnancy, the placenta. Follicle-stimulating hormone (FSH) stimulates the ovarian production of estrogens by the granulosa cells of the ovarian follicles and corpora lutea. Some estrogens are also produced in smaller amounts by other tissues such as the liver, pancreas, bone, adrenal glands, skin, brain, adipose tissue, and the breasts. These secondary sources of estrogens are especially important in postmenopausal women. The pathway of estrogen biosynthesis in extragonadal tissues is different. These tissues are not able to synthesize C19 steroids, and therefore depend on C19 supplies from other tissues and the level of aromatase. In females, synthesis of estrogens starts in theca interna cells in the ovary, by the synthesis of androstenedione from cholesterol. Androstenedione is a substance of weak androgenic activity which serves predominantly as a precursor for more potent androgens such as testosterone as well as estrogen. This compound crosses the basal membrane into the surrounding granulosa cells, where it is converted either immediately into estrone, or into testosterone and then estradiol in an additional step. The conversion of androstenedione to testosterone is catalyzed by 17β-hydroxysteroid dehydrogenase (17β-HSD), whereas the conversion of androstenedione and testosterone into estrone and estradiol, respectively is catalyzed by aromatase, enzymes which are both expressed in granulosa cells.
=== No development reported === AB-101 (RJ-101) – undefined mechanism of action – female sexual dysfunction [41] Apomorphine intranasal – non-selective dopamine receptor agonist, other actions – erectile dysfunction, female sexual dysfunction [42] Armodafinil ((R)-modafinil; D-modafinil; NH-02D; NH02D) – atypical dopamine reuptake inhibitor (DRI) – premature ejaculation [43] [44] Deuterated testosterone (d3-testosterone) – androgen (androgen receptor agonist) – female sexual dysfunction [45] Epelsiban (GSK557296; GSK-557296) – oxytocin receptor antagonist – premature ejaculation [46] Estradiol/testosterone topical gel (LibiGel-E/T; testosterone/estradiol topical gel) – combination of estradiol (estrogen) and testosterone (androgen) – female sexual dysfunction [47] Fibroblast growth factor 1 (FGF-1; FGF1; Acidic FGF; aFGF; Cardio Vascu-Grow; CVBT-141P; CVBT-141S; CVBT-141A; CVBT-141B; CVBT-141C; CVBT-141D; CVBT-141E; CVBT-141ED; CVBT-141F; CVBT-141G; CVBT-141H; FGF-1(141); VT-141D; VT-141ED; VT-141P; VT-141S) – fibroblast growth factor receptor (FGFR) agonist – erectile dysfunction [48] FKK-01PD (FKK-01PD; TGHW-01AP; TGHW01AP) – non-selective dopamine receptor agonist, other actions (apomorphine prodrug) – erectile dysfunction [49] GSK-958108 (GSK958108) – serotonin 5-HT1A receptor antagonist – premature ejaculation [50] HCP-1302 (HCP1302) – undefined mechanism of action – erectile dysfunction [51] Lidocaine topical gel – sodium channel blocker, local anesthetic – dyspareunia [52] PTL-2015 – undefined mechanism of action – erectile dysfunction [53] Research programme: nerve-targeted gene therapy - Periphagen (NC-3; NE-2; NE2-Endomorphin; NG-2; NG2-GAD; NN1-Neurotrophin) – various actions – erectile dysfunction [54] Research programme: sexual dysfunction therapy - Palatin Technologies (PL-6983) – melanocortin receptor modulators – erectile dysfunction, female sexual dysfunction [55] Sildenafil (KW-25084) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [56] Sildenafil orally soluble film (CURE-5003; CUREfilm Blue) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [57] Sildenafil oral spray (Duromist; NVD-401; SUD-003; SUD-004; SUDA-004; Sudamist) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [58] Tadalafil dry powder inhalation (Tadalafil Technosphere) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [59] Tadalafil orodispersible film tablet (Caliberi) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [60] Tadalafil topical (Extrinsa) – phosphodiesterase PDE5 inhibitor – female sexual dysfunction [61] Tadalafil/tamsulosin – combination of tadalafil (phosphodiesterase PDE5 inhibitor) and tamsulosin (α1-adrenergic receptor antagonist) – erectile dysfunction [62] Tunodafil (ecocarbamate; gluconocin; yonkenafil) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [63] Vilazodone (EMD-68843; SB-659746A; Viibryd) – serotonin reuptake inhibitor (SRI), serotonin 5-HT1A receptor agonist – sexual function disorders [64] Zotarolimus (ABT-578; Endeavor; Endeavor Resolute; MDT-4107 DES; Resolute DES; Resolute Integrity; Resolute Onyx; ZoMaxx) – FK-binding protein 12 (FKBP12) ligand and mechanistic target of rapamycin (mTOR) inhibitor – erectile dysfunction [65]
=== ZMAb === ZMAb is a mixture of three mouse mAbs: m1H3, m2G4, and m4G7. A study published in November 2013 found that EBOV-infected macaque monkeys survived after being given a therapy with a combination of three EBOV surface glycoprotein (EBOV-GP)-specific monoclonal antibodies (ZMAb) within 24 hours of infection. The authors concluded that post-exposure treatment resulted in a robust immune response, with good protection for up to 10 weeks and some protection at 13 weeks. ZMab was created by the NML and licensed to Defyrus, a Toronto-based biodefense company, with further funding by the Public Health Agency of Canada.
The brick, five-story Folger Coffee Company Building at 101 Howard in San Francisco, California is the former headquarters of Folgers. It is listed on the United States National Register of Historic Places. The building still has a sign saying "The Folgers Coffee Company" on one corner. On August 2, 2011, the Folger Building was purchased by the University of San Francisco, marking a return to the university's roots in downtown San Francisco.
Sources: en.wikipedia.org
=== EC 2.7.3: Phosphotransferases with a nitrogenous group as acceptor === EC 2.7.3.1: guanidinoacetate kinase EC 2.7.3.2: creatine kinase EC 2.7.3.3: arginine kinase EC 2.7.3.4: taurocyamine kinase EC 2.7.3.5: lombricine kinase EC 2.7.3.6: hypotaurocyamine kinase EC 2.7.3.7: opheline kinase EC 2.7.3.8: ammonia kinase EC 2.7.3.9: phosphoenolpyruvate—protein phosphotransferase EC 2.7.3.10: agmatine kinase EC 2.7.3.11: now EC 2.7.13.1, protein-histidine pros-kinase EC 2.7.3.12: now EC 2.7.13.2, protein-histidine tele-kinase EC 2.7.3.13: glutamine kinase
=== Hilary Wyndham === Hilary Wyndham (Mark Dexter) is a MD of the FX desk at Pierpoint. Throughout the first season, he is shown to be a more measured leader than his subordinate Kenny, an alcoholic and a bully who repeatedly subjects Yasmin to verbal abuse. However, nearing reduction-in-force (RIF) day, Hilary advises Yasmin not to report Kenny's behavior, telling her that being a "team player" would benefit her career prospects. Yasmin caves to Hilary's advice during her RIF interview when she denies having any negative experiences at Pierpoint, and Hilary vouches for her, ensuring that she is hired. In series 2, Hilary becomes paranoid about contracting COVID-19 at the office, wearing a mask to work and exhibiting germaphobe tendencies. Ironically, it is he who ends up falling ill and having to take time off from the office. Yasmin tells Hilary that she will be spending less time on the FX desk as she explores a move to the Private Wealth Management (PWM) division; Hilary, feeling numb and burnt out from the job, grants her his blessing. Hilary briefly reappears in series 4, now working for the Railways Pension Scheme (RPS); Eric calls him to invest in his and Harper's new short-only fund, SternTao, but Hilary kindly declines, stating that the RPS doesn't share their appetite for risk.
The most notable and recognisable series of advertisements was created by S. H. Benson's advertising, primarily drawn by the artist John Gilroy, in the 1930s and 1940s. Benson created posters that included phrases such as "Guinness for Strength", "Lovely Day for a Guinness", "Guinness Makes You Strong", "My Goodness My Guinness" (or, alternatively, "My Goodness, My Christmas, It's Guinness!"), and most famously, "Guinness Is Good for You". While modern alcohol advertising regulations prohibit such claims, vintage artefacts with the slogans remain common in Irish pubs.
The 2026 NCAA Division I men's basketball championship game is held at Lucas Oil Stadium in Indianapolis, in which the Michigan Wolverines beat the UConn Huskies 69–63 to win their second title and first since 1989. April 7 Iran war Trump warns that "a whole civilization will die tonight, never to be brought back again" unless Iran reaches a deal on reopening the Strait of Hormuz, and sets a deadline of 20:00 EDT. Following Trump's threat to "end its civilization", Democrats and former Republican congresswoman Marjorie Taylor Greene call for the invocation of the 25th amendment of the United States Constitution. Additionally, Democrats call for Trump to be impeached. Trump announces a two-week ceasefire that was mediated via Pakistan. He agrees to "suspend the bombing and attacks on Iran for a period of two weeks", subject to Iran agreeing to the "complete, immediate and safe opening" of the Strait of Hormuz, and to allow time for an agreement to be reached. Assistant District Attorney Clay Fuller, a Trump-endorsed Republican, wins the special election in Georgia to replace Marjorie Taylor Greene, who resigned in January following a public fallout with Trump. Judge Chris Taylor, the Democratic-backed candidate, wins election to the Wisconsin Supreme Court. The result expands the court's liberal majority to 5–2. AI firm Anthropic announces a new model for its Claude language model, named Mythos, designed for locating cybersecurity vulnerabilities and debugging. April 8 Trump threatens 50% tariffs on countries who distribute weapons to Iran.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.